REPARO

Clinical Trial

NCT01756456 Completed

REPARO

Evaluation of safety and efficacy of r-hNGF in patients with stage 2 and 3 Neurotrophic Keratitis (REPARO).

Phase 1/2

Interventional

Disease

Disease type

Other

Orphan drug recognition

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

23/05/2013

Closing date

06/03/2015

Inclusion criteria :

Exclusion criteria :

Funding

industry

Members involved

Others investigators

Pr Pierre FOURNIE

Representative

France

Anterior Segment Rare Eye Diseases (WG4), Registries & Epidemiology (TWG7), Research (TWG8)

Pr Daniel Böhringer

Representative

Germany

Anterior Segment Rare Eye Diseases (WG4)

Working Group Leader

Pr Elisabetta PILOTTO

Representative

Italy

Genetic Diagnostics (TWG6), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Dr Giacomo Maria Bacci

Representative

Italy

Anterior Segment Rare Eye Diseases (WG4), Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), Pediatric Ophthalmology Rare Diseases (WG3), Retinal Rare Eye Diseases (WG1)

Pr Isabelle Audo

Representative

France

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Dr Yannick Lemer

Representative

France

Dr Claudia Priglinger

Representative

Germany

Pr Philipp Albrecht

Representative

Germany

Dr JAIME ETXEBARRIA

Representative

Spain

Anterior Segment Rare Eye Diseases (WG4)

Dr BERNARDO F. SANCHEZ DALMAU

Representative

Spain

National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8)

Pr Julian Garcia Feijoo

Representative

Spain

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8)